CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to FMS

6 % Hydroxyethylstarch 130/0.4 = "Voluven®"

Phase 3
Fresenius Medical Care AG (FMS)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape
Drug Information

Target Indication

Sepsis

Clinical Trial

NCT00464204

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.